David S. Smith

Carnegie Mellon University is an American school that operates as a college or university. It is located in Pittsburgh, Pennsylvania.

Mylan Specialty LP develops, manufactures, and markets respiratory disease & allergy treatment products. The company was founded in 1978 and is headquartered in Morgantown, WV.

20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT.

CVERGENX, INC. operates as genomic informatics company. It provides decision-support to radiation oncologists to assist in radiation treatment planning. The company was founded by Javier F. Torres-Roca and Steven A. Eschrich and is headquartered in St. Petersburg, FL.

Portal Instruments, Inc. operates as a medical device company that focuses on drug delivery systems. It manufactures jet injectors that deliver drugs through the skin without a needle at specific depths and volumes. The firm engages in developing and commercializing a needle-free platform technology to transform the delivery of medicines and improve the patient experience. The company was founded by Patrick A. Anquetil and Ian W. Hunter in 2012 and is headquartered in Cambridge, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN.

Napa Valley Symphony operates as an orchestra. It offers musical performances. The company was founded by Jan Murray and is headquartered in Napa, CA.

Rimon Therapeutics Ltd. develops and markets pharmaceutical products. The company was founded by Michael May and is headquartered in Mississauga, Canada.

Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada.

Thermalin, Inc. engages in the development of insulin products for patients with diabetes. It offers stabilized, ultra-rapid, and highly concentrated; no refrigeration basal and mix; glucose-responsive smart basal; and StampPump insulins. The company was founded by Michael A. Weiss, Bruce H. Frank, and Richard Berenson in 2010 and is headquartered in Cleveland, OH.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Beta Bionics, Inc. operates a medical technology company leveraging lifelong, machine-learning, artificial intelligence to develop and commercialize the autonomous bionic pancreas. The company was founded by Edward R. Damiano in October 21, 2015 and is headquartered in Boston, MA.

The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada.

ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013.

zPREDICTA, Inc. develops organ-specific, physiologically-relevant 3D cell culture models witch provides 1-to-1 reconstruction of human tissues. The company was founded by Julia Kirshner and Mukti Parikh and is headquartered in San Jose, CA.

The Centre for the Commercialization of Antibodies & Biologics is a Canadian company that manufactures pharmaceutical products.

Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti.